These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 10388073)

  • 1. Positron Emission Tomography: Current Role for Diagnosis and Therapy Monitoring in Oncology.
    Strauss LG
    Oncologist; 1997; 2(6):381-388. PubMed ID: 10388073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
    Wu ZJ; Zhang YX; Wei H; Jia Q
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
    Dimitrakopoulou-Strauss A; Strauss L
    Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive diagnosis of solitary pulmonary lesions in cancer patients based on 2-fluoro-2-deoxy-D-glucose avidity on positron emission tomography/computed tomography.
    Bar-Shalom R; Kagna O; Israel O; Guralnik L
    Cancer; 2008 Dec; 113(11):3213-21. PubMed ID: 18924145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
    Metser U; Even-Sapir E
    Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET/CT for the staging and follow-up of patients with malignancies.
    Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
    Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer.
    Flamen P; Lerut A; Van Cutsem E; Cambier JP; Maes A; De Wever W; Peeters M; De Leyn P; Van Raemdonck D; Mortelmans L
    J Thorac Cardiovasc Surg; 2000 Dec; 120(6):1085-92. PubMed ID: 11088030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG-PET in the clinical management of Hodgkin lymphoma.
    Hutchings M; Eigtved AI; Specht L
    Crit Rev Oncol Hematol; 2004 Oct; 52(1):19-32. PubMed ID: 15363464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing tumor response to therapy.
    Weber WA
    J Nucl Med; 2009 May; 50 Suppl 1():1S-10S. PubMed ID: 19380403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current molecular imaging positron emitting radiotracers in oncology.
    Zhu A; Shim H
    Nucl Med Mol Imaging; 2011 Mar; 45(1):1-14. PubMed ID: 24899972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PET.
    Carlier T; Bailly C
    Front Med (Lausanne); 2015; 2():18. PubMed ID: 26090365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The sweet spot: FDG and other 2-carbon glucose analogs for multi-modal metabolic imaging of tumor metabolism.
    Cox BL; Mackie TR; Eliceiri KW
    Am J Nucl Med Mol Imaging; 2015; 5(1):1-13. PubMed ID: 25625022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel PET Radiotracers for Potential Use in Management of Lymphoma.
    Kostakoglu L
    PET Clin; 2012 Jan; 7(1):83-117. PubMed ID: 27157021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on Preoperative Parathyroid Localization in Primary Hyperparathyroidism.
    Park HS; Hong N; Jeong JJ; Yun M; Rhee Y
    Endocrinol Metab (Seoul); 2022 Oct; 37(5):744-755. PubMed ID: 36327985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amino Acid Transporters on the Guard of Cell Genome and Epigenome.
    Kahya U; Köseer AS; Dubrovska A
    Cancers (Basel); 2021 Jan; 13(1):. PubMed ID: 33401748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing a New Molecular Probe: The Potential Role for Tilmanocept (Lymphoseek
    Adesanya OO; Hutchinson CE
    Open Orthop J; 2017; 11():212-224. PubMed ID: 28458734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suture Granuloma With False-Positive Findings on FDG-PET/CT Resected via Laparoscopic Surgery.
    Takeshita N; Tohma T; Miyauchi H; Suzuki K; Nishimori T; Ohira G; Narushima K; Imanishi S; Toyozumi T; Matsubara H
    Int Surg; 2015 Apr; 100(4):604-7. PubMed ID: 25875540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymptomatic primary tuberculous pleurisy with intense 18-fluorodeoxyglucose uptake mimicking malignant mesothelioma.
    Shinohara T; Shiota N; Kume M; Hamada N; Naruse K; Ogushi F
    BMC Infect Dis; 2013 Jan; 13():12. PubMed ID: 23317113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.